UA23451C1 - - Google Patents
Download PDFInfo
- Publication number
- UA23451C1 UA23451C1 UA94063487A UA94063487A UA23451C1 UA 23451 C1 UA23451 C1 UA 23451C1 UA 94063487 A UA94063487 A UA 94063487A UA 94063487 A UA94063487 A UA 94063487A UA 23451 C1 UA23451 C1 UA 23451C1
- Authority
- UA
- Ukraine
- Prior art keywords
- training
- adzmol
- dose
- scopolamine
- urpi
- Prior art date
Links
- 238000012549 training Methods 0.000 description 13
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 10
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 10
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 10
- 229960002646 scopolamine Drugs 0.000 description 10
- 208000000044 Amnesia Diseases 0.000 description 7
- 208000031091 Amnestic disease Diseases 0.000 description 7
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 7
- 230000006986 amnesia Effects 0.000 description 7
- 230000003496 anti-amnesic effect Effects 0.000 description 7
- 229960004526 piracetam Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000037023 motor activity Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 235000013744 Passiflora ligularis Nutrition 0.000 description 1
- 240000004520 Passiflora ligularis Species 0.000 description 1
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 1
- 244000097202 Rathbunia alamosensis Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003109 amnesic effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- -1 ethylethylglycidyl sulfur Chemical compound 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960004122 phenibut Drugs 0.000 description 1
- DAFOCGYVTAOKAJ-UHFFFAOYSA-N phenibut Chemical compound OC(=O)CC(CN)C1=CC=CC=C1 DAFOCGYVTAOKAJ-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA94063487A UA23451C1 (fr) | 1994-06-16 | 1994-06-16 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA94063487A UA23451C1 (fr) | 1994-06-16 | 1994-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA23451C1 true UA23451C1 (fr) | 1999-12-29 |
Family
ID=50649870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA94063487A UA23451C1 (fr) | 1994-06-16 | 1994-06-16 |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA23451C1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014055054A1 (fr) * | 2012-10-05 | 2014-04-10 | Zagorii Gleb Vladimirovich | Utilisation de 1-adamantyl-éthyloxy-3-morpholino-2-propanol ou de ses sels pharmaceutiquement acceptables dans des compositions pharmaceutiques en tant que protection neurorétinienne |
| WO2014055055A1 (fr) * | 2012-10-05 | 2014-04-10 | Zagorii Gleb Vladimirovich | Composition pharmaceutique à base de 1-adamantyl-éthyloxy-3-morpholino-2-propanol et de ses sels pharmaceutiquement acceptables pour traiter une pathologie cérébrovasculaire et des maladies neurodégénératives du système nerveux central |
-
1994
- 1994-06-16 UA UA94063487A patent/UA23451C1/uk unknown
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014055054A1 (fr) * | 2012-10-05 | 2014-04-10 | Zagorii Gleb Vladimirovich | Utilisation de 1-adamantyl-éthyloxy-3-morpholino-2-propanol ou de ses sels pharmaceutiquement acceptables dans des compositions pharmaceutiques en tant que protection neurorétinienne |
| WO2014055055A1 (fr) * | 2012-10-05 | 2014-04-10 | Zagorii Gleb Vladimirovich | Composition pharmaceutique à base de 1-adamantyl-éthyloxy-3-morpholino-2-propanol et de ses sels pharmaceutiquement acceptables pour traiter une pathologie cérébrovasculaire et des maladies neurodégénératives du système nerveux central |
| CN104703586A (zh) * | 2012-10-05 | 2015-06-10 | 格列布·弗拉基米罗维奇·左格瑞 | 1-金刚烷乙氧基-3-吗啉基-2-丙醇或其药学上可接受的盐的药物组合物用于治疗脑血管病变和中枢神经系统中的神经退行性疾病 |
| EP2905017A4 (fr) * | 2012-10-05 | 2016-04-06 | Gleb Vladimirovich Zagorii | Composition pharmaceutique à base de 1-adamantyl-éthyloxy-3-morpholino-2-propanol et de ses sels pharmaceutiquement acceptables pour traiter une pathologie cérébrovasculaire et des maladies neurodégénératives du système nerveux central |
| US9333207B2 (en) | 2012-10-05 | 2016-05-10 | Gleb Vladimirovich Zagorii | Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cerebrovascular disease and neurodegenerative diseases of the central nervous system |
| US9545409B2 (en) | 2012-10-05 | 2017-01-17 | Gleb Vladimirovich Zagorii | Use of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof in pharmaceutical compositions as a neuroretinal protector |
| CN104703586B (zh) * | 2012-10-05 | 2017-04-26 | 格列布·弗拉基米罗维奇·左格瑞 | 1‑金刚烷乙氧基‑3‑吗啉基‑2‑丙醇或其药学上可接受的盐的药物组合物用于治疗脑血管病变和中枢神经系统中的神经退行性疾病 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Addolorato et al. | Deep transcranial magnetic stimulation of the dorsolateral prefrontal cortex in alcohol use disorder patients: effects on dopamine transporter availability and alcohol intake | |
| Pham et al. | Changes in brain nerve growth factor levels and nerve growth factor receptors in rats exposed to environmental enrichment for one year | |
| JACOBS et al. | Ultrastructural changes in the dorsal root and trigeminal ganglia of rats poisoned with methyl mercury | |
| Gasser | Contractures of skeletal muscle | |
| Freedman | Psychotomimetic drugs and brain biogenic amines | |
| Helmstetter et al. | Conditional hypoalgesia is attenuated by naltrexone applied to the periaqueductal gray | |
| Greenwood et al. | Voluntary wheel running: a useful rodent model for investigating mechanisms of stress robustness and exercise motivation | |
| Firemark et al. | The penetration of 2-PAM-C into brain and the effect of cholinesterase inhibitors on its transport | |
| Barbelivien et al. | Environmental enrichment increases responding to contextual cues but decreases overall conditioned fear in the rat | |
| Meyer-Bernstein et al. | Destruction of serotonergic neurons in the median raphe nucleus blocks circadian rhythm phase shifts to triazolam but not to novel wheel access | |
| Louilot et al. | Specificity of amygdalostriatal interactions in the involvement of mesencephalic dopaminergic neurons in affective perception | |
| Hamm et al. | Environmentally induced analgesia: an age-related decline in an endogenous opioid system | |
| Haakenson et al. | Effects of inactivation of the periaqueductal gray on song production in testosterone-treated male canaries (Serinus canaria) | |
| Ishikawa et al. | Effect of intraventricular γ-aminobutyric acid (GABA) on discrimination learning in rats | |
| Dewey et al. | Distribution of radioactivity in brain of tolerant and nontolerant pigeons treated with 3H-Δ9-tetrahydrocannabinol | |
| UA23451C1 (fr) | ||
| Ross et al. | Serial positive patterning: Implications for “occasion setting” | |
| Alonso et al. | Radioautographic evidence that axons from the area of supraoptic nuclei in the rat project to extrahypothalamic brain regions | |
| Richetto et al. | Comparison of the long-term consequences of withdrawal from repeated amphetamine exposure in adolescence and adulthood on information processing and locomotor sensitization in mice | |
| Bianchi et al. | Effects of some anti-epileptic drugs on brain acetylcholine | |
| DE69227609T2 (de) | Indolderivate und ihre Verwendung | |
| Lunam et al. | Substance P immunoreactive nerve fibres in the domestic chick ankle joint before and after acute urate arthritis | |
| Isaacson et al. | The effect of a calcium antagonist on the retention of simple associational learning | |
| Södersten et al. | Effects of vasopressin on female sexual behavior in male rats | |
| Hiramoto et al. | Effect of reserpine on retention of the conditioned NK cell response |